The ROR2–ASCL1 axis is validated as a molecular circuit where therapeutic pressure suppresses AR signaling, leading to ROR2 induction and downstream ASCL1-mediated reprogramming of the tumor lineage. The gene discussed is ROR2; the disease is neoplasm.